Listen
TARGINACT (oxycodone/naloxone), opioid agonist-antagonist combination
RHEUMATOLOGY - Focus
Opinions on drugs -
Posted on
Sep 10 2015
Reason for request
Re-assessment of the Actual Benefit and of the improvement in actual benefit
Low clinical benefit in severe and/or intractable pain in osteoarthritis of the knee or hip and in chronic lumbar pain
Insufficient clinical benefit in the other types of chronic, severe and/or intractable, non-cancer-related and non-neuropathic pain
- TARGINACT has Marketing Authorisation in the treatment of severe pain which can be adequately managed only with opioid analgesics. The opioid antagonist, naloxone, is added to counteract opioid induced constipation by blocking the action of oxycodone locally at opioid receptors in the gut.
- Its analgesic activity is equivalent to that of other forms of prolonged-release oxycodone, but its efficacy in opioid-induced constipation has not yet been fully established.
- In certain types of severe and/or intractable pain in osteoarthritis of the knee or hip and in chronic lumbar pain, TARGINACT is a 2nd line treatment in cases of opioid-induced constipation despite optimal management (dietary and lifestyle rules and administration of laxatives) in a treatment of last resort, at a stage when surgical options are being contemplated.
- These situations apart, it has no role in the treatment strategy for chronic non-cancer-related and non-neuropathic pain, particularly chronic inflammatory rheumatism, as mainly represented by rheumatoid arthritis and spondylarthritis.
Clinical Benefit
| Low |
- |
| Insufficient |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
-
English version
Contact Us
Évaluation des médicaments
